期刊文献+

人组织蛋白酶K在毕赤酵母中的表达、纯化及活性测定

Purification and Activity Determination of Human Cathepsin K Expressed in Pichia pastoris
下载PDF
导出
摘要 在动物和人的骨代谢疾病中,组织蛋白酶K是木瓜蛋白酶家族中的一种半胱氨酸蛋白酶,是负责骨吸收过程中溶骨的主要关键酶,是新药物的分子作用靶点。通过毕赤酵母表达系统表达出重组组织蛋白酶K,进一步用离子交换和分子筛系统进行纯化得到高纯度有活性的重组组织蛋白酶K。运用FluStar荧光酶标仪测定390 nm(激发光)和460 nm(发射光)波长下荧光强度的变化并计算出组织蛋白酶K的酶活力为119.6 U,为进一步筛选骨质疏松等骨代谢疾病的新药提供参考。 In the animal and human bone metabolic diseases,cathepsin K is a cysteine protease of the papain family,which is responsible for the resorption of the bone matrix and regarded as a key protease in bone resorption,and become the new drug molecule target.Active recombinant Cathepsin K was expressed in Pichia pastoris,and further purified by Ion Exchange chromatography and Size-Exclusion chromatography.Besides,the its changes of fluorescence intensity were measured at 390 nm excitation and 460 nm emission wavelengths by FluStar fluorescence microplate reader to calculate the enzyme activity of cathepsin K.The result showed that the enzyme activity of cathepsin K was 119.6 U.The research could provide a reference for the further screening of new drugs for osteoporosis and bone metabolic disease.
出处 《经济动物学报》 CAS 2013年第1期5-11,共7页 Journal of Economic Animal
基金 国际科技合作与交流资助项目(2011DFA32900)
关键词 组织蛋白酶K 毕赤酵母 表达纯化 活性测定 cathepsin K Pichia pastoris expression and purification determination of activity
  • 相关文献

参考文献7

二级参考文献128

  • 1张玉梅,谭宁华,黄火强,贾锐锐,曾广智,嵇长久.墨西哥落羽杉中三个活性双黄酮研究[J].云南植物研究,2005,27(1):107-110. 被引量:19
  • 2董爱森,金晓明.组织蛋白酶D作为乳癌预后指标的评价[J].国外医学(临床生物化学与检验学分册),1996,17(6):245-251. 被引量:1
  • 3刘玉胜,鹿庆华,蒋卫东.组织蛋白酶与细胞外基质重塑[J].基础医学与临床,2006,26(9):1037-1040. 被引量:11
  • 4吴艳,王毅,杨刚毅.组织蛋白酶K与骨质疏松的研究进展[J].中国骨质疏松杂志,2006,12(5):522-524. 被引量:4
  • 5[9]Lalonde,J. M.,Zhao,B. G.,Janson,C. A.,Alessio,K. J.,McQueney,M. S.,Orsini,M. J.,Debouck,C. M.,and Smith,W. W. (1999). The crystal structure of human procathepsin K. Biochemistry 38,862-869.
  • 6[10]Atley,L. M.,Mort,J. S.,Lalumiere,M.,and Eyre,D. R. (2000). Proteolysis of human bone collagen by cathepsin K: Characterization of the cleavage sites generating the cross-linked N-telopeptide neoepitope. Bone 26,241-247.
  • 7[11]Xia,L. H.,Kilb,J.,Wex,H.,Li,Z.,Lipyansky,A.,Breuil,V.,Stein,L.,Palmer,J. T.,Dempster,D. W.,and Bromme,D. (1999). Localization of rat cathepsin K in osteoclasts and resorption pits: inhibition of bone resorption and cathepsin K-activity by peptidyl vinyl-sulfones. Biol. Chem. 380,679-687.
  • 8[12]Katunuma,N.,Matsui,A.,Kakegawa,T.,Murata,E.,Asas,T.,and Ohba,Y. (1999). Study of the functional share of lysosomal cathepsins by the development of specific inhibitor. Advan. Enzyme. Regul. 39,247-260.
  • 9[13]Percival,M. D.,Ouellet,M.,Campagnolo,C.,Claveau,D.,and Li,C. (1999). Inhibition of cathepsin K by nitric oxide donors: evidence for the formation of mixd disulfides and a sulfenic acid. Biochemistry 38,13574-13583.
  • 10[14]Saftig,P.,Hunziker,E.,Wehmeyer,O.,Jones,S.,Boyde,A.,Romerskirch,W.,Moritz,J. D.,Schu,P.,and Figura,K. V. (1998). Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-K-deficient mice. Proc. Natl. Acad. Sci. USA. 95,13453-13458.

共引文献48

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部